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In order for some patients to benefit from aggressive chemotherapy for invasive breast 
carcinoma, many patients are currently being treated without little or no benefit. 
Enormous effort is hence being directed towards the identification of those patients who 
will need chemotherapy and those who will not. Since chemotherapy targets proliferating 
cells pathologists focus on the proliferative activity of tumors, as assessed by mitotic 
figure counts or by cell cycle specific immunohistochemical markers, such as Ki-67  and 
H3 histone. As far as the tumor grade is concerned, many of these studies have reported 
a tendency to up-grade carcinomas in resection specimen when compared to the initial 
diagnosis on the biopsy material, and most studies have noted that the upgrade in 
resection specimen is due solely or to a large extent to an increase in the mitotic figure 
count. In the present study, we propose a different explanation for the divergence in 
mitotic figure counts between biopsy and resection material. We assessed the 
proliferative activity of 52 invasive ductal carcinomas and confirm that the number of 
mitotic figures significantly increased by a factor of more than 3 in resection specimen 
over the biopsy material, while at the same time the pan-cell cycle specific marker MIB-1 
yieldes comparable results. we propose that the delayed formalin fixation of resection 
specimen allows cell cycle activities to continue for a long time, up to many hours, and 
that this leads to an arrest of mitoses in metaphase where they are readily identified by 
the pathologist. We propose that the mitotic figure count in the rapidly fixed biopsy cores 
better represent the tumor biology and should be used as a basis for chemotherapy 
therapeutic decisions.
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Introduction
In order for some patients to benefit from aggressive chemotherapy for invasive breast 
carcinoma, many patients are currently being treated without little or no benefit. Enormous effort 
is hence being directed towards the identification of those patients who will need chemotherapy 
and those who will not. Since chemotherapy targets proliferating cells (Amadori et al., 2000) 
pathologists focus on the proliferative activity of tumors, as assessed by mitotic figure counts or 
by cell cycle specific immunohistochemical markers, such as Ki-67 (Cattoretti et al., 1992) and 
H3 histone (Tapia et al., 2006). In fact, the mitotic figure count is a key element of the time-
honored gradeing of invasive breast carcinomas and has been routinely assessed in breast 
carcinomas for more than five decades (Elston and Ellis, 1991). Since the advent of core needle 
biopsies to diagnose breast lesions, many authors have systematically compared the results 
obtained in biopsy material with the results obtained in resection specimen. As far as the tumor 
grade is concerned, many of these studies have reported a tendency to up-grade carcinomas in 
resection specimen when compared to the initial diagnosis on the biopsy material, and most 
studies have noted that the upgrade in resection specimen is due solely or to a large extent to 
an increase in the mitotic figure count (Di Loreto et al., 1996; Dahlstrom et al., 1996; Sharifi et 
al., 1999; Denley et al., 1998; Harris et al., 2003; Badoual et al., 2005 Burge et al., 2006). 
Explanations for this phenomenon have been sought in intratumoral heterogeneity and in 
sampling artefacts, proposing that the biopsy material is either too small or taken at random 
from anywhere within the tumor and not necessarily from the proliferatively most active tumor 
periphery (Sharifi et al., 1999; Denley et al., 2000; Harris et al., 2003; Badoual et al., 2005 
Burge et al., 2006). It has even been suggested that discrepancies in tumor grades could be 
avoided by increasing the number and the size of the biopsy cores, but no hard data have ever 
been provided to underscore that idea (Harris et al.,2003; Badoual et al., 2005). Finally, several 
authors have put forward that in case of grade discrepancies, therapeutic decisions should be 
based on the grade obtained in the resection specimen (Denley et al, 2000; Lorgis et al., 2011). 
In the present study, we propose a different explanation for the divergence in mitotic figure 
counts between biopsy and resection material. We assessed the proliferative activity of 52 
invasive ductal carcinomas and confirm that the number of mitotic figures significantly increased 
by a factor of more than 3 in resection specimen over the biopsy material, while at the same 
time the pan-cell cycle specific marker MIB-1 yieldes comparable results. In contrast, we find 
that the proportion of post-metaphase figures (anaphase and telophase) among the counted 
mitoses in resection specimen is less than half of the number found in biopsies. Based on these 
findings, we propose that the delayed formalin fixation of resection specimen allows cell cycle 
activities to continue for a long time, up to many hours, and that this leads to an arrest of 
mitoses in metaphase where they are readily identified by the pathologist. We propose that the 
mitotic figure count in the rapidly fixed biopsy cores better represent the tumor biology and 
should be used as a basis for chemotherapy therapeutic decisions.
Methods
Patients: We selected 52 consecutive cases of invasive ductal carcinomas from the archives of 
the institute of pathology. Only those cases were chosen for which we disposed of paraffin 
blocks of true-cut biopsy material as well as resection specimen (tumorectomies or 
mastectomies). The slides were assigned random codes from 1 to 104 which were used for the 
entire series of experiments. No patient identifiers were used for any of the different part of the 
study. The study protocol was approved by the local ethical committee (CEV-VD BB09-15).
Mitotic figure counts: Hematoxylin and eosin stains were reformed according to standard 
protocols on 4µm section and used for mitotic figure counts. Mitoses were counted in 10 high 
power fields (Olympus BX-45 diagnostic microscope, 0.52mm diameter of the high power field), 
corresponding to grade cut-offs of 0-6 (grade 1), 7-14 (grade 2) and >15 (grade 3) (quote 
EUSOMA guidelines). As in our daily diagnostic routine, the guidelines of van Diest and 
coworkers (1992) were applied for the identification of mitotic figures. In biopsy material, areas 
were selected at random for mitotic figure counting typically where the high power field was 
filled with invasive carcinoma as much as possible. Ten complete high power fields could be 
counted in 47 or the 52 carcinomas, and in the remaining 5 cases, between 5 and 9 high power 
fields could be quantified. We had excluded from the study another 8 cases because we 
considered that insufficient material was contained in the biopsy core to permit a reliable 
comparison. In resection specimen, we selected the proliferatively most active tumor periphery, 
but avoiding hot-spots. Mitotic figures were counted jointly by two observers (HAL and CR) 
under a discussion microscope. Each mitotic figure was pointed out with an arrow in the 
microscope tube and only those mitoses were counted for which consensus was obtained by 
the both observers. We not only counted the total number of mitotic figures, but noted their 
phase of the cell cycle (prophase, prometaphase, metaphase, anaphase, and telophase, see 
figure 1). In addition, we estimated for each HPF the percentage of the field covered by tumor 
cells (vs. stroma and preexisting glands/lobules). In the same way, we counted the number of 
apoptotic figures per 10 HPF, again under a discussion microscope and by consensus between 
two observers (AN and CR).
Immunohistochemistry: Immunohistochemical assays were performed using an automated 
system from Ventana (Benchmal XL, Ventana, Tucson, AZ) on 4µm sections on super frost 
slides, after heat induced epitope retrieval (30min, EDTA buffer, proprietary information retained 
by Ventana). We used antibodies to Ki-67 (MIB-1, clone M7240, DAKO, Glostrup, Denmark, 
dilution 1:40) and the phosphorylated histone H3 (Ser28, clone 117C826, IMGENEX, San 
Diego, CA, dilution 1:1000). 
Quantification of MIB-1 immunostained slides was performed in three different ways: (i) rough 
estimation of the percentage of MIB-1 immunostained tumor cells, usually done at a 20x 
magnification and assessing about 3-5 fields in the biopsy at random or in the proliferatively 
active tumor periphery  in resection specimen, avoiding hotspots. In analogy to mitotic figure 
counting, MIB-1 estimation was performed by two observers (HAL and CR) using a discussion 
microscope and consensus was obtained for all cases. In practice, both observers jointly 
scanned about five to ten 20x fields for about 30seconds, each, made mental notes of our MIB-
1 based proliferative index, and then compared our results. In case of discrepancy, the case 
was discussed and a consensus index could be obtained in every case. (ii) The percentage of 
MIB-1 positive tumor cells was counted by hand (CR) on high quality color print-outs of five 
circular high power fields that were cropped from screen-shots of virtual microscope slides 
(Hamamatsu NanoZoomer, Hamamatsu City, Japan). (iii) Finally, we used the publicly available 
internet-based analysis software IMMUNORATIO to quantify the percentage of MIB-1 
immunostained tumor nuclei (http:// imtmicroscope.uta.fi/ immunoratio/), uploading jpg files of 
the circular high power fields cropped from the virtual slides. This software identifies the surface 
covered by hematoxcylin counterstained (blue) cells and the surface covered by 
immunoreactive (brown) cells and calculates an index of immunostained cells over the total cell 
number (Tuominen et al., 2010). Quantification of H3 immunohistochemistry was performed by 
estimating the number of immunoreactive (brown) cells among all tumor cells in five 20x fields.
Photoshop-based image analysis: We used photoshop-based image analysis to quantify the 
size of the biospy cylinders. For that purpose, the 52 biopsy slides were scanned using a 
commercially available flatbed scanner (EPSON perfection photo 3200) and the image was 
opened in Photoshop (version CS3, Adobe Systemc Inc, San José) on a MacPro (Apple 
computers, Cupertino, CA). In analogy to previously published procedures (Lehr et al., 1999), 
the biopsy cores were individually selected using the magic wand tool and the number of pixels 
(indicated in the histogram window) was then used to calculate the surface of the cores (in 
mm2). 
Statistical analysis: The data obtained in the various analyses were manually entered in an 
excel file and statistical analyses were calculated using a publicly available internet-based 
program (http://www.wessa.net/stat.wasp). We performed simple regression and Spearman 
analyses for the correlations between mitotic figure counts and immunohistochemical read-outs, 
and bivariate paired t-tests to compare the results obtained in biopsies with those obtained in 
resection specimen. P-values of <0.01 were considered statistically significant.
Results
52 breast carcinomas were analysed, from which we had slides and blocks of both true cut 
biopsies and resection specimen in our archive. The cases were from the years 2008 to 2011.
The number of mitoses per 10 high power fields ranged from 0 to 64 for biopsies and from 0 
to 250 for tumorectomies. Mean values ± SD were 6.23 ± 11.70 for biopsies and 19.99 ± 39.36 
(P=0.00800 paired t-test, A vs. I). The increase in the number of mitotic figures from the biopsy 
to the resection specimen was 3.43-fold (SD 3.71), with a range of 0.25 to 12.30. The results 
are shown in graphic form in Figure 1A. When the numbers of mitotic figures were 
normalized to the surface of the HPFs taken up by tumor cells (vs. stroma and preexisting 
glands/lobules), the numbers ranged from 0 tp 80 for biopsies and 0-263 for tumorectomies. 
Mean values ± SD were 10.11 ± 15.53 for biopsies and 21.12 ± 40.58 for tumorectomies 
(P=0.00737 paired t-test, Q vs. R). The increase in the number of mitotic figures from the biopsy 
to the resection specimen was 2.96-fold (SD 3.18), with a range of 0.08 to 18.90. The results 
are shown in graphic form in Figure 1B.
Motivated by the proposal by Harris (2003) and others that the discrepancy of mitotic figure 
counts between biopsies and resection specimen should be reduced by increasing the size of 
the biopsies, we correlated the increase of mitotic figure counts for each case pair with the size 
of the biopsy fragments, as assessed by Photoshop-based image analysis, which ranged from 
2.5 to 104mm2 (mean 9,6+/-14.3), but could not identify such a correlation (rho=0.01859, 
P=0.8952, Spearman I/A vs. CD)
We next analysed whether this increase in mitotic figures affect the overall grades of the 
respective carcinomas. We found that based on our mitotic figure counts (per 10HPF), 14 of the 
52 carcinomas were upgraded in the tumorectomies (26.9%; 6 from grade 1 to grade 2 and 8 
from grade 2 to grade 3) and 5 were downgraded (9.6%; 4 from grade 2 to grade 1 and 1 from 
grade 3 to grade 2). The concordance rate between grades in biopsies and resection specimen 
was 63.4%. Similar numbers were obtained when the mitotic figures are corrected for the 
tumor/stroma ratio: 15 carcinomas were upgraded (28.8%; 6 from grade 1 to grade 2 and 9 from 
grade 2 to grade 3) and 6 were downgraded (11.5%; 4 from grade 2 to grade 1). Concordance 
rate: 59.6%. If we compare this to the grades that were recorded in the original pathology 
reports of the respective patients, the observations were virtually superposable: 15 cases 
experienced an upgrade (28.8%; 5 from grade 1 to grade 2 and 10 from grade 2 to grade 3) and 
5 a downgrade (9.6%; 3 from grade 2 to grade 1 and 2 from grade 3 to grade 2). The 
concordance rate was 61.5%. These figures are at the lower end of the spectrum that has been 
reported by others (concordance rates between 62% and 81%; Di Loreto et al., 1996; Dahlstrom 
et al., 1996; Sharifi et al., 1999; Denley et al., 1998; Harris et al., 2003; Badoual et al., 2005 
Burge et al., 2006).
Next, we sub-classified the phases of the cell cycle of all the mitotic figures that we counted and 
found that there was a significant reduction in the percentage of post-metaphase figures 
(anaphase and telophase) from 6.93% of all mitotic figures in biopsies to 3.09% of all mitotic 
figures in resection specimen (P<0.005 paired Wilcoxon rank sum test with continuity correction 
AX vs AK). 
Along with the increase in mitotic figures in resection specimen, we observed an increase - 
albeit somewhat less pronounced when compared to mitotic figures - in the count of apoptotic 
figures per 10 high power fields from 10.4 ± 11.44  (mean +/- SD) to 15.4 ± 12.4 
(P=0.00261029 paired t-test H vs P).
We obtained MIB-1 immunohistochemical stains of all biopsies and tumorectomies and 
analyzed the percentage of MIB-1 stained tumor cells among all tumor cells by three different 
means: (i) rough estimation („eyeballing“) by two observers (HAL and CR), (ii) counting (on high 
quality color print-outs of circular areas, 0.74mm in diameters, cropped from digitized slides), 
and  (iii) image analysis using a IMMUNORATIO. We found that for all three modes of MIB-1 
quantification, there was no difference between biopsies and tumorectomies: 19.8% vs. 21.6% 
for eyeballed data (Fig. 2A), 21.7% vs. 22.4% for counted data and 14.2% vs. 13.6% for image 
analysis, biopsies versus tumorectomies, respectively (n.s. paired t-test). At the same time, the 
ratzion of MIB-1 over mitoses was significantly reduced in resection specimen (Fig. 2B). 
We next calculated simple linear regressions between mitotic figure counts (with and without 
correction for tumor/stroma ratio) and the percentage of MIB-1 positive nuclei (using the three 
distinct modes of assessment). The results are shown in table 1. 
Table 1: Linear regression analysis mitoses vs. MIB-1 immunohistochemistry in 
biopsies and tumorectomies/mastectomies
biopsies tumorectomies / mastectomies
mitoses/10HPF mitoses (corr) mitoses/10HPF mitoses (corr)
MIB-1 slope x=0.423 slope x=0.523 slope x=1.204 slope x=1.192
eyeballed rho=0.583 rho=0.472 rho=0.654 rho=0.514
P<0.00000582 P<0.00040464 P<0.0000001 P<0.000098
MIB-1 slope x=0.407 slope x=0.514 slope x=1.235 slope x=1.260
counted rho=0.546 rho=0.458 rho=0.644 rho=0.518
P<0.00002808 P<0.00064135 P<0.00000025 P<0.0000830
MIB-1 slope x=0.559 slope x=0.707 slope x=1.668 slope x=1.69
Immunor. rho=0.461 rho=0.396 rho=0.592 rho=0.496
P<0.00058774 P<0.0036890 P<0.0000038 P<0.0001847
We noted a strong, highly significant correlation between the number of mitotic figures and the 
percentage of MIB-1 positive tumor cells. The correlation was slightly stronger for uncorrected 
data (i.e. for mitotic figure counts than for mitotic figure counts that were corrected for the 
tumor/stroma ratio). The rho values for the correlation between MIB-1 and mitotic figure counts 
correspond well to data published previously by ourselves (Lehr et al., 1999) and others 
(Weidner et al.,  1994). It also became apparent – in agreement with the significantly higher 
numbers of mitoses in tumorectomies versus biopsies - that the slopes of the regression curves 
differ markedly between biopsies and resection specimen, so that for a comparable MIB-1 
index, the number of mitotic figures was consequently higher in the resection specimen than in 
the biopsies. These data are shown in graphic form in figure 3 for uncorrected mitoses and 
estimated MIB-1 values.
Using the paired t-test, we found highly significant differences concerning the ratio of MIB-1 
values over mitotic figures counts in biopsies and their corresponding resection specimen (P 
values were 0.00169, 0.000184, and 0.0000951 for estimated, counted, and computer-based 
MIB values over mitoses/10HPF and 0.0196, 0.00995, and 0.00517 over mitotic counts 
normalized to the tumor/stroma ratio, respectively, paired t-test BH/BI, BD/BE, AZ/BA and 
BJ/BK, BF/BG, and BB/BC).
The percentage of H3-immunostained cells per total number of tumor cells showed a high 
variation between cases and was comparable in biopsies and resection specimen (3.27+/- 3.21 
vs. 3.65+/- 3.67, n.s. paired Student t-test).
Discussion
This paper confirms observations made by other authors in the past, namely that the number of 
mitotic figures is higher in resection specimen of breast carcinomas than in core needle biopsies 
and that this results in an increase in tumor grades in around 25-35% of carcinomas (Di Loreto 
et al., 1996; Dahlstrom et al., 1996; Sharifi et al., 1999; Denley et al., 1998; Harris et al., 2003; 
Badoual et al., 2005 Burge et al., 2006). However, our interpretation of these data is 
fundamentally different from the one advanced in these previous reports. We do not believe that 
the discrepancy in mitotic figure counts is due to a sampling artefact, where biopsies are taken 
at random from anywhere within the tumor, and not necessarily the proliferatively active tumor 
periphery. If this was the case, the percentage of MIB-1 positive tumor cells should also be 
higher in resection specimen than in biopsies. However, neither our study (Fig 2A) nor results 
published by other authors suggest that this is the case (Cavaliere et al, 2005). Also, we have 
no reason to believe that the discrepancy in mitotic figure counts could be ascribed to the 
limited size of the biopsies (which could potentially preclude proper mitotic figure counting, 
Harris et al. 2003), because there appeared to exist no correlation between the size of the 
biopsies and the increase in mitotic figure counts between biopsies and resection specimen 
(rho=0.01859, P=0.8952).
Rather, we propose that the difference in mitotic figure counts between biopsies and resection 
specimen reflects a biological phenomenon, presumably secondary to intraoperative stress and 
specimen handling after removal from the breast. While biopsies are taken from the intact tumor 
and immediately immersed in formalin, resection specimen are exposed to intraoperative 
trauma and warm ischemia (i.e. due to ligation of feeding arteries to avoid bleeding), 
postoperative ischemia (i.e. during transport to radiology for specimen radiography and then on 
to pathology), and a poorly defined fixation delay in the formaldehyde container due to slow 
penetration of the fatty tissue by the fixative. If one assumes that formaldehyde penetrates 
tissues at a speed of 1mm/hour (Start et al., 1992), then the biopsy is entirely fixed within 
30min, arresting all biological processes. In contrast, tumor cells in the resection specimen may 
benefit from many additional hours of more or less unimpaired biological activity before 
eventually being stopped by dwindling energy sources or by being fixed by the slowly advancing 
formaldehyde front. With this consideration in mind, we assume that tumor cells, once having 
trespassed the G0/G1 checkpoint, are fatefully bound towards mitotic cell division. The cell 
cycle machinery will continue to work towards that aim even after removal of the tumor from the 
breast and metabolic activities are maintained by intracellular glucose through the Warburg 
effect. However, in the absence of sustained energy supply, the gradually declining energy 
reserves may eventually arrest the cell cycle at the G2/M checkpoint: recent studies have 
shown that the mitotic machinery involves a metabolic sensor, the AMP-activated protein kinase 
(AMPK, Koh & Chung, 2007) , which binds to various structures of the mitotic apparatus, 
including centrosomes, spindle poles, and the spindle midzone (Vazquez-Martin et al., 2009A). 
This mechanism is understood as en energy gauge that assures that the cell disposes of 
sufficient energy to complete faithful chromosome separation and thus exerts an important 
cytokinetic suppressor function (Vazquez-Martin et al., 2009B). It is conceivable that mitotic 
activity continues in resection specimen up to the G2/M checkpoint, and that in the absence of 
sufficient energy reserves, tumor cells arrest in metaphase, where they are easily identified and 
counted by the diagnosing pathologist. The fact that we found significantly fewer post-
metaphase figures (anaphase, telophase) in the resection specimen of our study (3% versus 
almost 7% in biopsies), would be consistent with such a concept. Also, this idea would reconcile 
the apparent dilemma that despite markedly increased mitotic figure counts, MIB-1 
immunoreaction seems not to go up in resection specimen (fig.2A and Cavaliere et al., 2005). 
MIB-1 labels all cells in the cell cycle (Cattoretti et al., 1992), including cells in S and in G2 
phase (which are not identifiable as proliferating cells in standard H&E sections), and would 
hence not be altered by a gradual (and artefactual) progress of these cells into mitose.
Finally, evidence for ongoing biological activity in resection specimen may also be drawn from 
the observation of significantly increased numbers of apoptotic figures in resection specimen 
when compared to biopsies, albeit to a smaller extent and likely involving other biological 
mechanisms then the ones considered to apply to mitoses (Klein et al., 2005).
In conclusion, we propose that the increased mitotic figure counts in resection specimen are 
secondary to poorly defined artefacts, which are probably quite variable from specimen to 
specimen and likely difficult to control in the clinical setting. Putative mechanisms include warm 
ischemia and/or protracted formalin fixation. Based in the consideration raised above, we 
propose that in the clinical routine, chemotherapy treatment decisions should be based on the 
assessment of mitotic figures in the biopsies, and not - as proposed by most authors - in the 
resection specimen (Harris et al., 2003; Badoual et al., 2005). This also suggest that in case of 
discrepancies, particular attention should be payed to the MIB-1 based proliferative activity, 
which appears not to be affected by the described problems. In fact, similar recommendations 
have been advanced also for other biomarkers, including hormone receptors and the Her2/neu 
status and should raise the awareness that good biopsy material of sufficient quantity and 
quality is an essential basis for (neo-) adjuvant treatment decisions, and that the examination of 
the resection specimen should be limited to additional informations concerning tumor extension 
and spread (size, lymphovascular invasion, resection margins, presence of associated in situ 
lesions).
H3: sensitive of delayed fixation, as suggested by Tapia et al., 2006. This has also been 
described by Hirata and coworkers (2004). May hence not work in resection specimen. It this 
due to a similar mechanism, where metaphase-arrested cells do not react with the antibody 
because the antigen degrades/desintegrates? 
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